KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis
NASDAQ:KRYS - Nasdaq - US5011471027 - Common Stock - Currency: USD
KRYS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. KRYS has an excellent financial health rating, but there are some minor concerns on its profitability. KRYS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make KRYS suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year KRYS was profitable.
In the past year KRYS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
KRYS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
KRYS has a Return On Assets of 8.44%. This is amongst the best in the industry. KRYS outperforms 95.07% of its industry peers.
KRYS's Return On Equity of 9.42% is amongst the best of the industry. KRYS outperforms 94.19% of its industry peers.
The Return On Invested Capital of KRYS (9.64%) is better than 95.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.44% | ||
| ROE | 9.42% | ||
| ROIC | 9.64% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 30.69%, KRYS belongs to the top of the industry, outperforming 97.71% of the companies in the same industry.
KRYS has a Operating Margin of 35.52%. This is amongst the best in the industry. KRYS outperforms 98.94% of its industry peers.
With an excellent Gross Margin value of 93.09%, KRYS belongs to the best of the industry, outperforming 92.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.52% | ||
| PM (TTM) | 30.69% | ||
| GM | 93.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KRYS is destroying value.
The number of shares outstanding for KRYS has been increased compared to 1 year ago.
The number of shares outstanding for KRYS has been increased compared to 5 years ago.
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
KRYS has an Altman-Z score of 27.83. This indicates that KRYS is financially healthy and has little risk of bankruptcy at the moment.
KRYS has a better Altman-Z score (27.83) than 96.48% of its industry peers.
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 27.83 |
ROIC/WACC0.94
WACC10.28%
2.3 Liquidity
KRYS has a Current Ratio of 7.28. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.28, KRYS is doing good in the industry, outperforming 69.72% of the companies in the same industry.
A Quick Ratio of 7.02 indicates that KRYS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.02, KRYS is doing good in the industry, outperforming 69.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.28 | ||
| Quick Ratio | 7.02 |
3. Growth
3.1 Past
KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 187.94%, which is quite impressive.
Looking at the last year, KRYS shows a very strong growth in Revenue. The Revenue has grown by 472.97%.
EPS 1Y (TTM)187.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%406.67%
Revenue 1Y (TTM)472.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.26%
3.2 Future
The Earnings Per Share is expected to grow by 51.74% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 35.05% on average over the next years. This is a very strong growth
EPS Next Y139.1%
EPS Next 2Y94.55%
EPS Next 3Y71.58%
EPS Next 5Y51.74%
Revenue Next Year58.1%
Revenue Next 2Y51.55%
Revenue Next 3Y42.24%
Revenue Next 5Y35.05%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
KRYS is valuated quite expensively with a Price/Earnings ratio of 56.22.
Based on the Price/Earnings ratio, KRYS is valued cheaply inside the industry as 93.13% of the companies are valued more expensively.
KRYS is valuated expensively when we compare the Price/Earnings ratio to 28.33, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 23.51, which indicates a rather expensive current valuation of KRYS.
93.66% of the companies in the same industry are more expensive than KRYS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.37, KRYS is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.22 | ||
| Fwd PE | 23.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaper than 93.66% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, KRYS is valued cheaply inside the industry as 94.19% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.76 | ||
| EV/EBITDA | 36.65 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 71.58% in the coming years.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y94.55%
EPS Next 3Y71.58%
5. Dividend
5.1 Amount
KRYS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KRYS (4/23/2025, 2:43:34 PM)
168.09
-0.71 (-0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.71%
Inst Owner Change0.36%
Ins Owners11.97%
Ins Owner Change-1.47%
Market Cap4.86B
Analysts84.71
Price Target219.1 (30.35%)
Short Float %11.33%
Short Ratio10.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.47%
Min EPS beat(2)-0.73%
Max EPS beat(2)27.68%
EPS beat(4)1
Avg EPS beat(4)-15.87%
Min EPS beat(4)-80.01%
Max EPS beat(4)27.68%
EPS beat(8)2
Avg EPS beat(8)-14.64%
EPS beat(12)5
Avg EPS beat(12)-8.57%
EPS beat(16)7
Avg EPS beat(16)-8.54%
Revenue beat(2)0
Avg Revenue beat(2)-1.08%
Min Revenue beat(2)-1.26%
Max Revenue beat(2)-0.9%
Revenue beat(4)1
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-6.45%
Max Revenue beat(4)5.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.59%
PT rev (3m)3.38%
EPS NQ rev (1m)-3.6%
EPS NQ rev (3m)35.71%
EPS NY rev (1m)19.11%
EPS NY rev (3m)19.47%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)6.75%
Revenue NY rev (1m)0.33%
Revenue NY rev (3m)-0.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.22 | ||
| Fwd PE | 23.51 | ||
| P/S | 16.72 | ||
| P/FCF | 40.76 | ||
| P/OCF | 39.36 | ||
| P/B | 5.13 | ||
| P/tB | 5.13 | ||
| EV/EBITDA | 36.65 |
EPS(TTM)2.99
EY1.78%
EPS(NY)7.15
Fwd EY4.25%
FCF(TTM)4.12
FCFY2.45%
OCF(TTM)4.27
OCFY2.54%
SpS10.05
BVpS32.75
TBVpS32.75
PEG (NY)0.4
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.44% | ||
| ROE | 9.42% | ||
| ROCE | 10.82% | ||
| ROIC | 9.64% | ||
| ROICexc | 25.81% | ||
| ROICexgc | 25.81% | ||
| OM | 35.52% | ||
| PM (TTM) | 30.69% | ||
| GM | 93.09% | ||
| FCFM | 41.02% |
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 63.12% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.29% | ||
| Profit Quality | 133.67% | ||
| Current Ratio | 7.28 | ||
| Quick Ratio | 7.02 | ||
| Altman-Z | 27.83 |
F-Score6
WACC10.28%
ROIC/WACC0.94
Cap/Depr(3y)534.57%
Cap/Depr(5y)974.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)187.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%406.67%
EPS Next Y139.1%
EPS Next 2Y94.55%
EPS Next 3Y71.58%
EPS Next 5Y51.74%
Revenue 1Y (TTM)472.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%116.26%
Revenue Next Year58.1%
Revenue Next 2Y51.55%
Revenue Next 3Y42.24%
Revenue Next 5Y35.05%
EBIT growth 1Y206.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year271.59%
EBIT Next 3Y83.87%
EBIT Next 5YN/A
FCF growth 1Y218.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y238.98%
OCF growth 3YN/A
OCF growth 5YN/A